Scholar Rock Holding Corporation (SRRK)
Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment
Scholar Rock Holding Corp. SRRK said on Sunday the company will present new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.
Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript
Scholar Rock Holding Corporation. (NASDAQ:SRRK ) Q4 2024 Earnings Conference Call February 27, 2025 8:15 AM ET Company Participants Jay Backstrom - President & CEO Ted Myles - COO & CFO Tracey Sacco - Chief Commercial Officer Conference Call Participants Allison Bratzel - Piper Sandler Michael Yee - Jefferies Tessa Romero - JPMorgan Gary Nachman - Raymond James Operator Good morning and welcome to Scholar Rock's Fourth Quarter Financial Results and Business Update Call.
Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth
Scholar Rock Holding Corporation SRRK President & CEO Jay Backstrom presented at the J.P. Morgan Healthcare Conference.
Scholar Rock Holding Corporation (SRRK) Q3 2024 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q3 2024 Earnings Conference Call November 12, 2024 8:15 AM ET Company Participants Jay Backstrom - President & CEO Ted Myles - COO & CFO Conference Call Participants Jenna Lee - Jefferies Etzer Darout - BMO Capital Markets Gary Nachman - Raymond James Alex Nugent - Truist Securities Limited Operator Good morning and welcome to Scholar Rock's Third Quarter 2024 Financial Results and Business Update Call. All participants will be in listen-only mode.
Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross?
Scholar Rock Holding Corporation (SRRK) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, SRRK's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Here's Why Everybody's Talking About Scholar Rock Right Now
Successful clinical-trial results recently made Scholar Rock one of the stock market's top performers.
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal
Scholar Rock stock skyrockets as the late-stage study of the investigational therapy, apitegromab, to treat spinal muscular atrophy meets the primary goal.
Scholar Rock (SRRK) Shares Surge on Successful SMA Drug Trial
Shares of Scholar Rock Holding Corp. (SRRK, Financial) soared by 335% as their candidate drug for spinal muscular atrophy (SMA), apitegromab, achieved the primary endpoint in a Phase 3 trial. The positive results indicate that the apitegromab monoclonal antibody significantly improves motor function in patients.
Scholar Rock: SMA Program Strides Forward With Positive Clinical Data
Apitegromab met the primary endpoint in its phase 3 SAPPHIRE study for spinal muscular atrophy, setting up BLA & MAA filings in Q1 2025. Apitegromab is the first treatment targeting muscle fiber atrophy in SMA, potentially changing the standard of care and offering a competitive edge. Scholar Rock also has apitegromab being explored in a phase 2 study for obesity, with clinical data expected in Q2 2025, presenting another catalyst.
Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points on Monday.
Scholar Rock's stock soars more than 200% on positive trial of treatment for spinal muscular atrophy
The Phase 3 trial of Apitegromab showed statistically significant improvement in motor function.
